Geron Posts $183.6M 2025 Revenue, Plans $220–240M RYTELO Sales in 2026
Geron’s 2025 net product revenue reached $183.6 million with Q4 sales of $48 million, reflecting a 9 % rise in demand and expansion to 1,300 ordering accounts. The company cut one-third of its workforce, shifted R&D costs to capitalized manufacturing, and forecasts RYTELO sales of $220–240 million for 2026 despite pricing pressures in Europe.
1. 2025 Financial Results
In 2025 Geron achieved net product revenue of $183.6 million, driven by RYTELO shipments that generated $48 million in Q4. Demand climbed 9%, expanding the product’s ordering base to around 1,300 accounts globally.
2. Operational Restructuring
To reduce operating expenses, Geron reduced its workforce by approximately one-third and reclassified RYTELO-related R&D spending into capitalized manufacturing costs, reflecting its shift from development to commercial scale-up.
3. 2026 Outlook and Challenges
The company projects RYTELO net product revenue of $220–240 million for 2026 while navigating intensifying gross-to-net deductions and complex European pricing negotiations, with 10+ investigator trials ongoing and data updates expected in H2 2026.